PHP257 Comparison of Economic Evaluation Between Three Major HTA Agencies. Is There a French Touch?  by Levy, P et al.
A558  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  
with final appeal results were included in the study. The appeals were grouped under 
broader disease area categories and the appeal decision materials were reviewed. 
The grounds of appeals and outcomes of each appeal were extracted. Summary 
statistics were used to present the number of rejected or upheld appeals. Results: 
The most common area of NICE appeals is oncology followed by rheumatology and 
respiratory diseases. More than 50% of the total appeals were lodged in oncology in 
which 30% were breast cancer. The majority of the appeals identified were dismissed 
by the appeal panel on all grounds submitted, whilst approximately a third of the 
appeals were upheld on individual points. ConClusions: The majority of appeals 
submitted to NICE have been rejected by the appeal panel on all grounds. This study 
has only summarized outcomes from NICE appeals, further analysis is required to 
assess factors that influence whether appeals are upheld.
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Biosimilars: accessing tHe Uk market
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objeCtives: The EMA has in place evolving guidelines on biosimilars since 2005. 
Biologics Price Competition and Innovation Act (BPCIA) passed by the US Congress 
in 2009 brought focus on biosimilars in the US. The impending expiration of patents 
for many top-selling biologics has also made biosimilars commercially exciting. This 
research evaluates the national and local market access challenges facing biosimi-
lars in the short to medium term. Methods: Formal current positions from HTA 
bodies like NICE, SMC, AWMSG, as well as positions at a national level from payers in 
the NHS in England, Scotland, and Wales, where available, are reviewed to inform the 
national market access situation. Local market access considerations like focus on 
budgets, pricing, discounts and stakeholder perceptions are evaluated by checking 
formulary uptake of two recently (2015) launch biosimilars for infliximab – Remsima 
and Inflectra. Results: NICE, SMC, and the NHS in Scotland recently have or are 
known to be working on formal positions on biosimilars. NICE (for STAs) and SMC 
have recently decided not to appraise biosimilars and there were no questions from 
the AWMSG for the biosimilars it accepted for use recently. However, expected (30%) 
and actual (10%) list-price reductions have not matched. Local discounts, budget 
considerations as well as payer, physician, and patient perception can play a crucial 
role in getting biosimilars on formularies. ConClusions: The number of biosimi-
lars accessing the UK market is rising. By all counts formal HTA assessments are 
not to be regularly expected in the UK, leaving such agencies to focus on innovative 
medicines at a national level. Decision on access to biosimilars in the UK hinges 
crucially on local market issues like price and perception.
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objeCtives: To review and compare HTA reports produced by two Italian 
Regions: Veneto and Emilia Romagna. To highlight analogies and differences 
between the elements evaluated in the reports and the outcomes of the assess-
ments made. Methods: A descriptive analysis of HTA reports produced by the 
Coordinamento Regionale Unico sul Farmaco (CRUF) of Veneto and Commissione 
Regionale del Farmaco (CRF) of Emilia Romagna. In order to obtain a direct compari-
son on the assessment methods of the two regions, only reports regarding the same 
active principles were considered. The analysed reports were published between 
2011 and 2014. Coherently with the principle of transparency professed by these HTA 
institutions, all the data included in the analysis were directly obtained from the 
agencies’ websites. Results: For all of the 5 drugs analysed in the reports, Veneto 
and Emilia Romagna considered same elements, such as safety, comparators, indica-
tion, and concluded the identical results about them. Both Regions provided always 
the same efficacy studies; in 2 cases Emilia Romagna evaluated more secondary 
endpoints, while in 1 it considered more studies than Veneto, nevertheless the two 
regions drew equal conclusions about efficacy. Different approaches were taken 
when conducting economic evaluations: both Regions considered drugs’ costs but 
Emilia Romagna, on the contrary of Veneto, never developed neither a budget impact 
analysis nor a target population study. Finally, in 3 out of 5 cases Commissions 
drew different conclusions about the selection of patients to which give the drug 
to or whether including or not the drug in the Prontuario Terapeutico Regionale 
(PTR). ConClusions: Divergences in final decisions highlight different priorities 
of each HTA region regarding the criteria used to make evaluations. Because of the 
goal of transparency both Regions have, the lack of evidence of mechanisms they 
adopt in taking assessments should be filled.
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objeCtives: The newly established French Economic Evaluation and Public Health 
Commission (CEESP) provides recommendations and opinions to decision mak-
ers about economic evaluations (EEs) for innovative and expensive treatments. 
In this context, our aim was to compare the differences between EEs conducted 
in three major health authorities in Europe: SMC, NICE and CEESP. Methods: 
Using the Prismaccess database, we identified all technology appraisals (TAs), 
excluding vaccines, published by CEESP prior to June 2015. For these products, 
we sought corresponding guidance published by English and Scottish agencies 
(NICE, SMC) and compared methodology and results of the EEs. Data collected 
for each TA included: study population, comparator, type of analysis, model, time 
horizon, perspective, clinical and utility data, costs and results. Results: We 
Prior to any indication of a potential privacy risk, 31% of consumers indicate they 
would be very likely to download an EHR mobile application (rated 6 or 7 on 7-point 
Likert scale; 4.0 mean). This likelihood decreased with age. After introducing variable 
levels of privacy risk, and within the multivariate framework, age and educational 
level revealed inverse statistical associations with risk tolerance (greater age and 
educational achievement were less likely to download the hypothetical app). In 
contrast, higher income levels and higher levels of patient satisfaction with their 
physicians were associated with greater likelihood to download. These results were 
statistically significant at α = 0.05. ConClusions: One in three consumers reports 
they would be very likely to download an EHR mobile application. Younger demo-
graphics are more likely to download the app and are more accepting of risk of those 
data being leaked to a 3rd party. While the likelihood to download the app increases 
with income level, higher levels of education may actually reduce the likelihood 
of downloading. Physician satisfaction is also a driver of increased likelihood to 
download the application.
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objeCtives: 90% of the German population is insured in the statutory health 
insurance which covers nearly all healthcare services with only little co-payments. 
German health insurance claims data therefore constitute an important basis for 
real world evidence (RWE) on morbidity and healthcare costs. Aim of this study was 
to investigate to which extent RWE was used for estimation of prevalence and inci-
dence in German AMNOG assessments since introduction 4 years ago and its impact 
on price discounts. Methods: German AMNOG dossiers with published benefit 
assessments until March 2015 were evaluated. They were screened for use of RWE 
in assessing prevalence and incidence and also target populations. After descrip-
tion and discussion of methods and data sources used, statistics were applied to 
explore a potential influence of use and quality of RWE data on magnitude of price 
discounts. Results: 134 AMNOG dossiers were included of which 50% utilized 
RWE to assess prevalence, incidence, and target populations. German claims data 
were employed in 16 dossiers (24%), registry data in 7 dossiers (10%), and other data 
sources like Delphi panels in 49 dossiers (73%). Claims data were mostly applied 
for prevalence estimations of both the underlying disease and target populations. 
Compared to numbers stated by the Federal Joint Committee, target populations 
were accepted as reported in 56% and underrated numbers in 44% of those dossiers 
specifically using claims data. Price negotiations were completed for 80 AMNOG 
assessments. A t-test evaluating the association between use of RWE and negotiated 
price discounts indicated that price discounts were lower in assessments that did 
incorporate RWE data (p= 0.049). ConClusions: German claims data constitute 
a valuable and valid data source for assessing epidemiologic evidence in German 
AMNOG assessments and can be a valuable tool for subsequent price negotiations.
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objeCtives: To assess guidance for using single-arm studies in indirect compari-
sons (ICs) to support health technology assessment submissions. ICs enable com-
parison of different treatments using data from separate studies. The published 
methodology for conducting ICs outline the requirement for multiple arm studies 
to form connections between direct and indirect evidence. This is not possible when 
trials have single arms, a particular issue for treatments for new indications or 
for rare diseases. Methods: Guidelines were searched for advice on the use of 
single-arm trial data in ICs: National Institute of Health and Care Excellence [NICE], 
Cochrane; Centre for Reviews and Dissemination; and Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses. In addition the NICE website was searched 
for new drug submissions including single-arm studies in ICs. Results: There is 
minimal current guidance for dealing with single-arm studies in ICs. NICE recom-
mends that such analyses should be treated as observational and appropriate steps 
taken to adjust for possible bias. There are very few submissions where single-arm 
trial evidence has been used in an IC. Those that attempted to compare outcomes 
from single-arm studies were mostly in oncology and in many cases the reviewing 
committee had requested this additional information. Cost-effectiveness calcula-
tions using these data were acknowledged as being highly unreliable, even after 
attempts had been made to adjust for possible between-study bias. ConClusions: 
A number of methods could be used to compare results across multiple single-arm 
studies. A Bayesian hierarchical model that includes random effects allowing for 
heterogeneity between studies is a good choice. However, there is a need for clear 
guidance from organisations such as NICE and Cochrane, who provide recommen-
dations on carrying out systematic reviews and indirect comparisons, on this and 
other approaches to synthesising information from single-arm studies.
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objeCtives: In order for NICE to issue final guidance regarding a new or existing 
medicine to the NHS, the appeal period for the technology appraisal has to have 
passed and if an appeal is submitted, it has to be resolved. The Appeal Panel con-
siders appeals which meet one or more of the grounds of appeal defined by NICE. 
The objective of this study was to identify the past appeal decisions and report 
the respective results. Methods: A review of past NICE appeals decisions was 
conducted via a comprehensive search of the NICE website. Published technology 
appraisals in which appeals were lodged were identified. Only completed appraisals 
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objeCtives: In 2006, Conditional Marketing Authorisation (MA) was implemented 
by the European Medicines Agency (EMA) to ensure early access to innovative medi-
cations for patients in Europe. The objective of this study is to compare the health 
technology assessment (HTA) process in France, England, and Germany for medi-
cines having received a conditional approval over the past 9 years Methods: The 
present study concerned all medicines having been approved with a conditional 
MA. The HTA assessments performed by three national bodies, IQWiG, NICE and 
HAS, were compared for these products. Results: Of the 19 medicines for which 
a conditional MA was requested, 17 have received an approval of this type. Three 
of these approved medicines have not yet been assessed by any of the three HTA 
bodies, or are currently undergoing assessment. Four medicines have undergone 
HTA assessment by all three agencies. An additional 9 medicines have been assessed 
in two of the three countries (4 by both HAS and NICE and 5 by both HAS and 
IQWiG). Whereas all products assessed by HAS received a favourable opinion for 
reimbursement, NICE and IQWiG are more restrictive in their recommendations. 
Indeed, only 1/8 medicines assessed by NICE received a favourable recommendation 
and 5/ 9 by IQWiG. Of note, a specific regulatory framework has been implemented in 
Germany by which IQWiG considers all orphan products approved by EMA to provide 
an added medical benefit. This disposition concerned 4 of the 5 products having 
received a favourable opinion in Germany. ConClusions: The HTA assessments 
by HAS, IQWiG and NICE of medicines having received a conditional approval are 
heterogeneous and lead to differing reimbursement statuses. Different criteria are 
taken into consideration, including the relevance of the comparator, the clinical 
trial design and endpoints as well as the relevant target population and health 
economic assessment.
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objeCtives: In 2014 the Catalan Health Service (CatSalut) published a guide (GAEIP) 
which describes the methodology for the economic evaluation of medicines in 
Catalonia. Now the objective is to design the operational aspects to introduce both 
the economic evaluations (EE) and budget impact analyses (BIA) of medicines in the 
three Health Technology Assessment (HTA) programmes of CatSalut. Methods: 
The Commission for Economic Evaluation and Budget Impact (CAEIP) of CatSalut 
led the project that: 1) reviewed the processes undertaken by other countries that 
use EE/BIA of medicines; 2) ran focus groups with representatives of each of the 
three HTA programmes: primary and community care (PHF-APC), hospital medicines 
administered in ambulatory care (PHF-MHDA), and orphan medicines (PASFTAC); 
3) validated the proposal through pilots in each programme. Results: The pro-
ject delivered a general framework to implement the EE and BIA in the current 
processes of each of the three HTA programmes, allowing them to fit it into their 
timings and particular needs. According to this proposal, companies will submit 
their EE and BIAs of medicines in a similar way to what they currently do in single 
technology appraisals. The HTA programmes will assess the quality of the submitted 
information, and may ask for additional analyses when required. To date, the pilot 
on the therapeutic area of oncology has been completed (PHF-MHDA) whilst the 
other two are still ongoing. CAEIP also developed a set of formularies to be used by 
the companies when submitting the required information. Finally, the project was 
informative, as it highlighted the size the resources needed to implement this new 
process within the HTA programmes. ConClusions: CatSalut continues with the 
deployment of EE and BIA as it believes both to be valuable when issuing recom-
mendations on the use and the therapeutic positioning of medicines within the 
Catalan health system.
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objeCtives: ED processes between manufacturers, Regulators and HTAs was 
developed to improve quality of evidence and patient access to new medicines. 
SEED is a pilot project financed by the EC involving 14 EU HTAs. Sanofi engaged in 
HTA ED with or without Regulators in four different occasions. This is an overview 
of lessons learnt and suggestions for future improvements. Methods: In order 
to collect quantitative and qualitative information on the execution of the pilots 
and to evaluate their impact on evidence generation, Sanofi conducted a cross 
sectional analysis amongst all departments involved in the four EDs through: - An 
ad hoc questionnaire probing quality of process, feedback and consensus across 
agencies - Candid meetings to refine response interpretation. Results: Approval 
requests, Briefing Book (BB) completions and clarifications were straightforward, 
although coordination was sometimes lacking. Process timelines seemed appro-
priate, nevertheless great variability in Sanofi’s efforts was observed depending on 
the therapeutic area and the type of advice sought. Teams were generally satisfied 
with the meetings, with good contributions from stakeholders and topics properly 
addressed. However, relevant items not reported in the BB could not be raised dur-
ing the discussion, not all attendees were involved in national negotiations and 
patients were not consistently represented. The quality of the feedback before, 
during and after the meeting was satisfactory. Yet, seeking consensus across HTAs 
was not observed, nor the final report always consistent with meeting discus-
sions. ConClusions: Sanofi satisfaction about the ED experience was gener-
ally high, allowing to pressure test evidence development plans and scenarios, 
while garnering feedback on critical items from multiple countries. In order to 
truly improve evidence generation, some flexibility during the meeting should be 
allowed and consensus of opinion/advice achieved. All teams agreed on consulting 
in similar EDs in the future.
identified four products: trastuzumab emtansine, sofosbuvir, dolutegravir and 
riociguat. All had been assessed by CEESP and SMC; only one NICE assessment 
was published (sofosbuvir). For all products, except sofosbuvir, the type of model 
was different between agencies. All the published CEESP opinions reviewed cost-
effectiveness (CEA) and cost-utility analyses (CUA) whereas SMC and NICE only 
published CUA. Comparators and perspectives used were also different. For tras-
tuzumab emtansine, the Incremental Cost Effectiveness Ratio (ICER) published 
by SMC was 26.5% lower than the one published by CEESP. According to SMC 
guidance, riociguat and dolutegravir were dominant versus comparators, whereas 
CEESP published ICERs of 108 876 € /QALY and 16 526 € /QALY respectively. For 
sofosbuvir, most UK ICERs were higher than French ones. ConClusions: Results 
confirm differences in recommendations and methodological requirements 
between the three agencies. Comparator heterogeneity due to different local 
practices appears to be a key factor leading to discrepancies in ICERs and cost-
effectiveness assessment. ICERs were higher in France than in the UK, possibly 
due to absence of established thresholds and no explicit impact on reimbursement 
decision.
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objeCtives: Persistently stubborn infant mortality rates across the world have 
prompted the use of mobile technologies to assist in vaccine adherence. This sys-
tematic review attempts to assess the efficacy of a mobile phone technology in 
delivering timely infant immunization reminders and ensuring compliance and 
follow-up rates. Methods: Studies were identified based on pre-specified criteria 
from two journals (BMJ and Lancet) and three databases (PUBMED, Google Scholar 
and Cochrane). The articles were screened for PICO (Population, Intervention, 
Control and Outcome) parameters and subsequently shortlisted when they included 
the desired target population, namely infants and mothers and used the methodol-
ogy of Randomized Controlled Trials (RCTs). Biases on account of dropouts, selection 
and blinding methods were taken into consideration. Risk ratios were analyzed for 
the review using a forest plot and bias graphs. Results: A total of 71 studies were 
identified based on results of which 3 duplicates were excluded. Of the 68, 25 were 
screened for PICO parameters and eventually of the 22 full-text articles reviewed. 
6 were RCTs and qualified as relevant for the Health Technology Assessment. The 
studies, published between 1996 and 2014, recorded the participation of 5999 infants 
and mothers across 5 clinic based interventions and 1 province-based intervention. 
A risk ratio of 0.67 indicates that the mobile-based intervention is 45% more effective 
than the control, suggesting the former to be a crucial measure to improve outcome 
measures such as timeliness of immunization and increased infant vaccine aware-
ness. ConClusions: Our analysis suggests that the use of mobile technologies 
could marginally improve compliance in the intervention groups, even if they do not 
affect the overall immunization rates. The evidence also shows that incorporating 
this scheme into an existing health system requires a small investment that could 
potentially result in sizeable gains in reducing infant and neonatal mortality and 
morbidity, particularly in resource-limited settings.
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objeCtives: There has been significant discussion on implementing a single Health 
Technology Assessment (HTA) process in Europe, in part because of the high level of 
variability among existing agencies. Agencies often disagree on the reimbursement 
decisions and on the economic and clinical conclusions. While disagreement on eco-
nomic evaluations and reimbursement decisions can be explained by different agency 
remits and healthcare budgets, the driving factors of and justifications for clinical var-
iability are currently unknown. This analysis examines drivers of clinical variability, 
specifically the clinical comparator, and uses case studies to explore instances where 
different comparators were used. Methods: 198 reviews from NICE, SMC, PBAC, HAS 
and CADTH’s Common Drug Review were analyzed. Therapeutics were matched on 
indication, and the most recent review since 2007 for each agency was included if it 
was also reviewed by NICE. Agreement with NICE on the clinical comparator(s) used 
and on clinical evaluations were evaluated. Results: Agreement with NICE on the 
clinical comparator(s) ranged from 40% to 65%. Other agencies agreed with NICE’s 
clinical evaluations slightly more often when they also agreed on the comparator (54% 
vs. 45%); however, this trend was not statistically significant (p= .31). Case study evalu-
ations indicated that differences in country standards of care and agencies’ willing-
ness to accept comparators used in the clinical trials were common concerns in cases 
of comparator disagreement. ConClusions: While there appears to be variability 
between NICE and the other agencies in comparator(s) evaluated, this does not appear 
to be a driving factor in clinical variability. Where differences in comparator(s) exist, 
a main theme identified was the differences in standards of care between countries. 
If agencies evaluate different comparators because of local standards of care, differ-
ent agencies would have to be willing to accept comparators not in line with their 
standard practices in order to implement a pan-European system.
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